Combination tumor immunotherapy with radiotherapy and Th1 cell therapy against murine lung carcinoma

Clinical and Experimental Metastasis

Volumn 24, Issue 7, 2007, Pages 533-540

  Yokouchi, Hiroshi ^a,b   Chamoto, Kenji ^a   Wakita, Daiko ^a   Yamazaki, Koichi ^b   Shirato, Hiroki ^b   Takeshima, Tsuguhide ^b   Dosaka Akita, Hirotoshi ^c   Nishimura, Masaharu ^b   Yue, Zhang ^a   Kitamura, Hidemitsu ^a   Nishimura, Takashi ^a  

^a HOKKAIDO UNIVERSITY   (Japan)

^b HOKKAIDO UNIVERSITY   (Japan)

^c HOKKAIDO UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

Author keywords

Draining lymph node; Immunotherapy; Irradiation; Lung cancer; Th1 cells

Indexed keywords

OVALBUMIN; TETRAMER; TUMOR ANTIGEN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIGEN EXPRESSION; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER IMMUNIZATION; CANCER IMMUNOTHERAPY; CANCER RADIOTHERAPY; CD8+ T LYMPHOCYTE; CELL THERAPY; CONTROLLED STUDY; CYTOTOXIC T LYMPHOCYTE; CYTOTOXICITY; EXPERIMENTAL MOUSE; FEMALE; LUNG CARCINOMA; MOUSE; NONHUMAN; TH1 CELL; TREATMENT INDICATION; TUMOR GROWTH; TUMOR IMMUNITY;

ANIMALS; ANTIGENS, NEOPLASM; CARCINOMA, LEWIS LUNG; COMBINED MODALITY THERAPY; IMMUNOTHERAPY, ADOPTIVE; MICE; MICE, INBRED C57BL; OVALBUMIN; T-LYMPHOCYTES, CYTOTOXIC; TH1 CELLS;

EID: 34948852757     PISSN: 02620898     EISSN: None     Source Type: Journal    
DOI: 10.1007/s10585-007-9090-x     Document Type: Article

References (34)

1. Canney PA, Dean S (1990) Transforming growth factor beta: a promoter of late connective tissue injury following radiotherapy? Br J Radiol 63(752):620-623
2. Broski AP, Halloran PF (1994) Tissue distribution of IL-10 mRNA in normal mice. Evidence that a component of IL-10 expression is T and B cell-independent and increased by irradiation. Transplantation 57(4):582-592
3. + regulatory T cell subsets. J Leuko Biol 74(4):471-478
4. Friedman EJ (2002) Immune modulation by ionizing radiation and its implications for cancer immunotherapy. Curr Pharm Des 8(19):1765-1780
5. Garnett CT, Palena C, Chakarborty M, Tsang KY, Schlom J, Hodge JW (2004) Sublethal irradiation of human tumor cells modulate phenotype resulting in enhanced killing by cytotoxic T lymphocytes. Cancer Res 64(21):7985-7994
6. Dybal EJ, Haas GP, Maughan RL, Sud S, Pontes JE, Hillman GG (1992) Synergy of radiation therapy and immunotherapy in murine renal cell carcinoma. J Urol 148(4):1331-1337
7. Lumniczky K, Desaknai S, Mangel L, Szonde B, Hamada H, Hidvegi EJ, Safrany G (2002) Local tumor irradiation augments the antitumor effect of cytokine-producing autologous cancer cell vaccines in a murine glioma model. Cancer Gene Ther 9(1):44-52
8. Hillman GG, Slos P, Wang Y, Wright JL, Layer A, De Meyer M, Yudelev M, Che M, Forman JD (2004) Tumor irradiation followed by intratumoral cytokine gene therapy for murine renal adenocarcinoma. Cancer Gene Ther 11(1):61-72
9. Nikitina EY, Gabrilovich DI (2001) Combination of γ-irradiation and dendritic cell administraion induces a potent antitumor response in tumor-bearing mice: approach to treatment of advanced stage cancer. Int J Cancer 94(6):825-833
10. Teitz-Tennenbaum S, Li Q, Rynkiewicz S, Ito F, Davis MA, McGinn CJ, Chang AE (2003) Radiotherapy potentiates the therapeutic efficacy of intratumoral dendritic cell administration. Cancer Res 63(23):8466-8475
11. Honeychurch J, Glennie MJ, Johnson PWM, Illidge TM (2003) Anti-CD40 monoclonal antibody therapy in combination with irradiation results in a CD8 T-cell-dependent immunity to B-cell lymphoma. Blood 102(4):1449-1457
12. Plautz GE, Inoue M, Shu S (1996) Defining the synergistic effects of irradiation and T-cell immunotherapy for murine intracranial tumors. Cell Immunol 171(2):277-284
13. Ganss R, Ryschich E, Klar E, Arnold B, Hammerling GJ (2002) Combination of T-cell therapy and trigger of inflammation induces remodeling of the vasculature and tumor eradication. Cancer Res 62(5):1462-1470
14. Cao ZA, Daniel D, Hanahan D (2002) Sub-lethal radiation enhances anti-tumor immunotherapy in a transgenic mouse model of pancreatic cancer. BMC cancer 2:11
15. Milas L, Mason KA, Ariga H, Hunter N, Neal R, Valdecanas D, Krieg AM, Whisnant JK (2004) CpG oligodeoxynucleotide enhances tumor response to radiation. Cancer Res 64(15):5074-5077
16. Mason KA, Ariga H, Neal R, Valdecanas D, Hunter N, Krieg AM, Whisnant JK, Milas L (2005) Targeting toll-like receptor 9 with CpG oligodeoxynucleotides enhances tumor response to fractionated radiotherapy. Clin Cancer Res 11(1):361-369
17. Nishimura T, Iwakabe K, Sekimoto M, Ohmi Y, Yahata T, Nakui M, Sato T, Habu S, Tashiro H, Sato M, Ohta A (1999) Distinct role of antigen-specific T helper type 1 (Th1) and Th2 cells in tumor eradication in vivo. J Exp Med 190(5):617-628
18. Nishimura T, Nakui M, Sato M, Iwakabe K, Kitamura H, Sekimoto M, Ohta A, Koda T, Nishimura S (2000) The critical role of Th1-dominant immunity in tumor immunology. Cancer Chemother Pharmacol 46(Suppl):S52-61
19. Chamoto K, Kosaka A, Tsuji T, Matsuzaki J, Sato T, Takeshima T, Iwakabe K, Togashi Y, Koda T, Nishimura T (2003) Critical role of the Th1/Tc1 circuit for the generation of tumor-specific CTL during tumor eradication in vivo by Th1-cell therapy. Cancer Sci 94(10):924-928
20. Ikeda H, Chamoto K, Tsuji T, Suzuki Y, Wakita D, Takeshima T, Nishimura T (2004) The critical role of type-1 innate and acquired immunity in tumor immunotherapy. Cancer Sci 95(9):697-703
21. Davis ID, Jefford M, Parente P, Cebon J (2003) Rational approaches to human cancer immunotherapy. J Leuko Biol 73(1):3-29
22. Schiller JH, Pugh M, Kirkwood JM, Karp D, Larson M, Borden E (1996) Eastern cooperative group trial of interferon gamma in metastatic melanoma: an innovative study design. Clin Cancer Res 2(1):29-36
23. Ohta A, Sato N, Yahata T, Ohmi Y, Santa K, Sato T, Tashiro H, Habu S, Nishimura T (1997) Manipulation of Th1/Th2 balance in vivo by adoptive transfer of antigen-specific Th1 or Th2 cells. J Immunol Methods 209(1):85-92
24. Ohta S, Tsukamoto H, Watanabe K, Makino K, Kuge S, Hanai N, Habu S, Nishimura T (1995) Tumor-associated glycoantigen, sialyl Lewis (a) as a target for bispecific antibody-directed adoptive tumor immunotherapy. Immunol Lett 44(1):35-40
25. Yokouchi H, Chamoto K, Wakita D, Noguchi D, Yamazaki K, Dosaka-Akita H, Nishimura M, Ikeda H, Nishimura T (2006) Tetramer-blocking assay for defining antigen-specific cytotoxic T lymphocytes using peptide-MHC tetramer. Cancer Sci 97(2):148-154
26. Lee PP, Yee C, Savage PA, Fong L, Brockstedt D, Weber JS, Johnson D, Swetter S, Thompson J, Greenberg PD, Roederer M, Davis MM (1999) Characterization of circulating T cells specific for tumor-associated antigens in melanoma patients. Nature Med 5(6):677-685
27. Lee KH, Wang E, Nielsen MB Wunderlich J, Migneles S, Connors M, Steinberg SM, Rosenberg SA, Marincola FM (1999) Increased vaccine-specific T cell frequency after peptide-based vaccination correlates with increased susceptibility to in vitro stimulation but does not lead to tumor regression. J Immunol 163(11):6292-6300
28. Chamoto K, Tsuji T, Funamoto H, Kosaka A, Matsuzaki J, Sato T, Abe H, Fujio K, Yamamoto K, Kitamura T, Takeshima T, Togashi Y, Nishimura T (2004) Potentiation of tumor eradication by immunotherapy with T-cell receptor gene-transduced T-helper type 1 cells. Cancer Res 64(4):386-390
29. Gyobu H, Tsuji T, Suzuki Y, Ohkuri T, Chamoto K, Kuroki M, Miyoshi H, Kawarada Y, Kato H, Takeshima T, Nishimura T (2004) Generation and targeting of human tumor-specific Tc1 and Th1 cells transduced with a lentivirus containing a chimeric immunoglobulin T-cell receptor. Cancer Res 64(4):1490-1495
30. Shinagawa N, Yamazaki K, Onodera Y, Miyasaka K, Kikuchi E, Dosaka-Akita H, Nishimura M (2004) CT-guided transbronchial biopsy using an ultrathin bronchoscope with virtual bronchoscopic navigation. Chest 125(3):1138-1143
31. Shirato H, Shimizu S, Shimizu T, Nishioka T, Miyasaka K (1999) Real-time tumour-tracking radiotherapy. Lancet 353(9161):1331-1332
32. Fukumoto S, Shirato H, Shimizu S, Ogura S, Onimaru R, Kitamura K, Yamazaki K, Miyasaka K, Nishimura M, Dosaka-Akita H (2002) Small-volume image-guided radiotherapy using hypofractionated coplanar, and noncoplanar multiple fields for patients with inoperable stage I nonsmall cell lung carcinomas. Cancer 95(7):1546-1553
33. Harada T, Shirato H, Ogura S, Oizumi S, Yamazaki K, Shimizu S, Onimaru R, Miyasaka K, Nishimura M, Dosaka-Akita H (2002) Real-time tumor-tracking radiation therapy for lung carcinoma by the aid of insertion of a gold marker using bronchofiberscopy. Cancer 95(8):1720-1727
34. Onimaru R, Shirato H, Shimizu K, Kitamura K, Xu B, Fukumoto S, Chang TC, Fujita K, Oita M, Miyasaka K, Nishimura M, Dosaka-Akita H (2003) Tolerance of organs at risk in small-volume hypofractionated, image-guided radiotherapy for primary and metastatic lung cancers. Int J Rad Oncol Biol Phys 56(1):126-135